Article Text



Statistics from

Review of adverse events following off-label use of medicines by G. Diesel (VR, February 26, 2011, vol 168, pp 205–207; doi: 10.1136/vr.d1128). This report contained an incorrect statement regarding the contraindications for Convenia 80 mg/ml powder and solvent for solution for injection for dogs and cats (Pfizer) and concurrent use of NSAIDs. The Summary of Product Characteristics for Convenia includes advice concerning the concurrent use of NSAIDs which may compete with cefovecin for protein binding sites and thus may cause adverse effects. This is advice, and not a specific contraindication as stated in the report. The error is regretted.

View Abstract

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles